Sumitomo Mitsui’s DS Asset Management subsidiary backed the neurological and metabolic disorder drug developer in a round that will support clinical trials.

D&D Pharmatech, a diversified Korea-based drug developer backed by pharmaceutical firm DongKoo Bio&Pharma, has received $51m in a series C round led by Praxis Capital Partners.

The round also featured DS Asset Management, a subsidiary of financial services firm Sumitomo Mitsui Financial Group, in addition to venture capital fund Kudos Ventures and asset manager Korea Investment & Securities.

Founded in 2014, D&D owns several purpose-built companies focusing on treatments for conditions ranging from obesity and metabolic disorders like diabetes to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn